- Home
- ABUS vs PVLA Comparison
ABUS vs PVLA Comparison
Compare ABUS & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABUS
- PVLA
- Stock Information
- Founded
- ABUS 2005
- PVLA 2015
- Country
- ABUS United States
- PVLA United States
- Employees
- ABUS N/A
- PVLA N/A
- Industry
- ABUS Biotechnology: Pharmaceutical Preparations
- PVLA Biotechnology: Pharmaceutical Preparations
- Sector
- ABUS Health Care
- PVLA Health Care
- Exchange
- ABUS Nasdaq
- PVLA Nasdaq
- Market Cap
- ABUS 906.7M
- PVLA 888.0M
- IPO Year
- ABUS N/A
- PVLA N/A
- Fundamental
- Price
- ABUS $4.57
- PVLA $81.40
- Analyst Decision
- ABUS Strong Buy
- PVLA Strong Buy
- Analyst Count
- ABUS 2
- PVLA 13
- Target Price
- ABUS $5.00
- PVLA $99.38
- AVG Volume (30 Days)
- ABUS 932.9K
- PVLA 163.2K
- Earning Date
- ABUS 11-13-2025
- PVLA 11-11-2025
- Dividend Yield
- ABUS N/A
- PVLA N/A
- EPS Growth
- ABUS N/A
- PVLA N/A
- EPS
- ABUS N/A
- PVLA N/A
- Revenue
- ABUS $14,606,000.00
- PVLA N/A
- Revenue This Year
- ABUS $138.02
- PVLA N/A
- Revenue Next Year
- ABUS N/A
- PVLA N/A
- P/E Ratio
- ABUS N/A
- PVLA N/A
- Revenue Growth
- ABUS 116.64
- PVLA N/A
- 52 Week Low
- ABUS $2.71
- PVLA $11.17
- 52 Week High
- ABUS $5.10
- PVLA $85.30
- Technical
- Relative Strength Index (RSI)
- ABUS 51.26
- PVLA 59.88
- Support Level
- ABUS $4.41
- PVLA $78.99
- Resistance Level
- ABUS $4.87
- PVLA $85.03
- Average True Range (ATR)
- ABUS 0.24
- PVLA 5.58
- MACD
- ABUS -0.01
- PVLA -0.02
- Stochastic Oscillator
- ABUS 40.91
- PVLA 63.39
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
About PVLA Palvella Therapeutics Inc. Common Stock
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.